Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

A clinician nudge for referral to a gynecologic oncologist at the time of suspected ovarian cancer diagnosis improved referral rates by 20 percentage points, according to study results.Nearly a third ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...

today announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC in an oral presentation at the Society of Gynecologic Oncology (SGO ...

The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in ...

M.D., Director of Clinical & Translational Gynecologic Oncology Research at the University of Pennsylvania, and lead principal ...